Lei-Bo Xu, Chao Liu, Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Research Center of Medicine, Sun Yat-sen University, Guangzhou 510120, Guangdong Province, China.
World J Stem Cells. 2014 Nov 26;6(5):579-90. doi: 10.4252/wjsc.v6.i5.579.
Liver cancer is an aggressive disease with a high mortality rate. Management of liver cancer is strongly dependent on the tumor stage and underlying liver disease. Unfortunately, most cases are discovered when the cancer is already advanced, missing the opportunity for surgical resection. Thus, an improved understanding of the mechanisms responsible for liver cancer initiation and progression will facilitate the detection of more reliable tumor markers and the development of new small molecules for targeted therapy of liver cancer. Recently, there is increasing evidence for the "cancer stem cell hypothesis", which postulates that liver cancer originates from the malignant transformation of liver stem/progenitor cells (liver cancer stem cells). This cancer stem cell model has important significance for understanding the basic biology of liver cancer and has profound importance for the development of new strategies for cancer prevention and treatment. In this review, we highlight recent advances in the role of liver stem cells in hepatocarcinogenesis. Our review of the literature shows that identification of the cellular origin and the signaling pathways involved is challenging issues in liver cancer with pivotal implications in therapeutic perspectives. Although the dedifferentiation of mature hepatocytes/cholangiocytes in hepatocarcinogenesis cannot be excluded, neoplastic transformation of a stem cell subpopulation more easily explains hepatocarcinogenesis. Elimination of liver cancer stem cells in liver cancer could result in the degeneration of downstream cells, which makes them potential targets for liver cancer therapies. Therefore, liver stem cells could represent a new target for therapeutic approaches to liver cancer in the near future.
肝癌是一种具有高死亡率的侵袭性疾病。肝癌的治疗主要取决于肿瘤分期和基础肝病。不幸的是,大多数病例在癌症已经进展时才被发现,错过了手术切除的机会。因此,深入了解导致肝癌发生和发展的机制将有助于发现更可靠的肿瘤标志物,并开发用于肝癌靶向治疗的新小分子药物。最近,“癌症干细胞假说”的证据越来越多,该假说认为肝癌起源于肝干细胞/祖细胞(肝癌干细胞)的恶性转化。这种癌症干细胞模型对理解肝癌的基本生物学具有重要意义,并对癌症预防和治疗新策略的发展具有深远意义。在这篇综述中,我们强调了肝干细胞在肝癌发生中的作用的最新进展。我们对文献的回顾表明,鉴定细胞起源和涉及的信号通路是肝癌中具有治疗意义的挑战性问题。虽然在肝癌发生中不能排除成熟肝细胞/胆管细胞的去分化,但肿瘤干细胞亚群的癌变更能解释肝癌的发生。肝癌中肝癌干细胞的消除可能导致下游细胞的退化,这使它们成为肝癌治疗的潜在靶点。因此,肝干细胞可能成为未来肝癌治疗的新靶点。